Metformin versus Insulin for the Treatment of Gestational Diabetes
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metformin is a logical treatment for women with gestational diabetes mellitus, but randomized trials to assess the efficacy and safety of its use for this condition are lacking. METHODS: We randomly assigned 751 women with gestational diabetes mellitus at 20 to 33 weeks of gestation to open treatment with metformin (with supplemental insulin if required) or insulin. The primary outcome was a composite of neonatal hypoglycemia, respiratory distress, need for phototherapy, birth trauma, 5-minute Apgar score less than 7, or prematurity. The trial was designed to rule out a 33% increase (from 30% to 40%) in this composite outcome in infants of women treated with metformin as compared with those treated with insulin. Secondary outcomes included neonatal anthropometric measurements, maternal glycemic control, maternal hypertensive complications, postpartum glucose tolerance, and acceptability of treatment. RESULTS: Of the 363 women assigned to metformin, 92.6% continued to receive metformin until delivery and 46.3% received supplemental insulin. The rate of the primary composite outcome was 32.0% in the group assigned to metformin and 32.2% in the insulin group (relative risk, 0.99 [corrected]; 95% confidence interval, 0.80 [corrected] to 1.23 [corrected]). More women in the metformin group than in the insulin group stated that they would choose to receive their assigned treatment again (76.6% vs. 27.2%, P<0.001). The rates of other secondary outcomes did not differ significantly between the groups. There were no serious adverse events associated with the use of metformin. CONCLUSIONS: In women with gestational diabetes mellitus, metformin (alone or with supplemental insulin) is not associated with increased perinatal complications as compared with insulin. The women preferred metformin to insulin treatment. (Australian New Zealand Clinical Trials Registry number, 12605000311651.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While individual RCTs support limited efficacy of metformin (73,74) and glyburide (75) in reducing glucose levels for the treatment of GDM, these agents are not recommended as the first-line treatment for GDM because they are known to cross the placenta and data on long-term safety for offspring is of some concern (35).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [73]
In the citing paper
“It was concluded that metformin alone, or with supplemental insulin, was not associated with increased perinatal complications.”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [112]
In the citing paper
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [90]
In the citing paper
“Blood glucose-lowering pharmacological therapy is effective at improving outcomes in women with gestational diabetes whose hyperglycemia does not respond sufficiently to lifestyle therapy (71, 82, 88–90).”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [89]
In the citing paper
“Glyburide is effective in controlling blood glucose in women with gestational diabetes”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [90]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Dabelea, D., Hanson, R. L., Lindsay, R. S., Pettitt, D. J., Imperatore, G., Gabir, M. M., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2208 · Cited by 1,277
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924
Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes
Ben‐Haroush, A., Yogev, Y., & Hod, M. (2004) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00985.x · Cited by 856
Gestational diabetes: The consequences of not treating
Langer, O., Yogev, Y., Most, O., & Xenakis, E. M. J. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.11.039 · Cited by 677
Silverman, B. L., Metzger, B. E., Cho, N. H., & Loeb, C. A. (1995) · Diabetes Care · doi:10.2337/diacare.18.5.611 · Cited by 643
Hoffman, L., Nolan, C., Wilson, J. D., Oats, J. J. N., & Simmons, D. (1998) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb140192.x · Cited by 570
An Increase in the Incidence of Gestational Diabetes Mellitus: Northern California, 1991–2000
Ferrara, A., Kahn, H. S., Quesenberry, C. P., Riley, C., & Hedderson, M. M. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000113623.18286.20 · Cited by 452
Glueck, C. J., Phillips, H., Cameron, D., Sieve-Smith, L., & Wang, P. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01666-6 · Cited by 430
Research works printed but not linked: 3
- Coetzee EJ, 1980, S Afr Med J, 58, 795
- Coetzee EJ, 1984, S Afr Med J, 65, 635
- Gutzin SJ, 2003, Can J Clin Pharmacol, 10, 179
Cited by
Items 401–500 of 1,001
Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome
Raperport, C., Chronopoulou, E., & Homburg, R. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2021.1889366 · Cited by 26
“It has also been proposed as a strategy to prevent pregnancy complications and early miscarriages [60,61].”
BackgroundLi, C., Gao, C., Zhang, X., Zhang, L., Shi, H., & Jia, X. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.2015761 · Cited by 25
“A total of 2 studies (893 patients with GDM) recorded neonatal anthropometric results (Head circumference, Height, Chest circumference) comparing insulin and metformin [37,38].”
BackgroundInfluentialForetz, M., & Viollet, B. (2014) · médecine/sciences · doi:10.1051/medsci/20143001018 · Cited by 36
Reynolds, R. M., Denison, F. C., Juszczak, E., Bell, J. L., Penneycard, J. M., Strachan, M. W. J., Lindsay, R. S., Alexander, C. I., Love, C. D. B., Whyte, S., et al. (2017) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-017-1505-3 · Cited by 22
Metformin in gestational diabetes mellitus: predictors of poor response
Gante, I., Melo, L. A. G., Dores, J. M., Ruas, L., & Almeida, M. D. C. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0486 · Cited by 21
Eid, S. R., Moustafa, R. S. I., Salah, M. M., Hanafy, S. K., Aly, R. H., Mostafa, W. G., & Ghanem, A. I. M. (2018) · Egyptian Pediatric Association Gazette · doi:10.1016/j.epag.2018.01.002 · Cited by 24
Garbarino, V. R., Santos, T. A., Nelson, A. R., Zhang, W. Q., Smolik, C. M., Javors, M. A., Daws, L. C., & Gould, G. G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.013 · Cited by 24
Berry, D. C., Thomas, S., Dorman, K. F., Ivins, A., Abreu, M. D. L. Á., Young, L., & Boggess, K. (2018) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-018-2108-3 · Cited by 21
Huhtala, M. S., Tertti, K., Juhila, J., Sorsa, T. A., & Rönnemaa, T. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-03077-6 · Cited by 26
Ardilouze, A., Bouchard, P., Hivert, M., Simard, C., Allard, C., Lapointe‐Garant, M., Ménard, J., Ouellet, A., Houde, G., Pesant, M.-H., et al. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.02.004 · Cited by 22
Sénat, M., & Deruelle, P. (2016) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2016.01.009 · Cited by 41
Prevention of Hypertensive Disorders of Pregnancy—Is There a Place for Metformin?
Poniedziałek‐Czajkowska, E., Mierzyński, R., Dłuski, D. F., & Leszczyńska‐Gorzelak, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132805 · Cited by 22
“The results of a study by Martis et al., who compared the effect of insulin on the course and outcomes of pregnancy in women with GDM with oral hypoglycemic drugs, including metformin, seem to be intriguing.”
BackgroundInfluentialEfficacy of metformin in pregnant obese women: a randomised controlled trial
Chiswick, C. A., Reynolds, R. M., Denison, F. C., Whyte, S., Drake, A. J., Newby, D. E., Walker, B. R., Forbes, S., Murray, G. D., Quenby, S. M., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006854 · Cited by 21
Effects of Common Equine Endocrine Diseases on Reproduction
Burns, T. A. (2016) · Veterinary Clinics of North America Equine Practice · doi:10.1016/j.cveq.2016.07.005 · Cited by 20
Gestational diabetes mellitus—right person, right treatment, right time?
Lindsay, R. S., Mackin, S. T., & Nelson, S. M. (2017) · BMC Medicine · doi:10.1186/s12916-017-0925-2 · Cited by 27
“Metformin does have an advantage in being associated with less weight gain than either insulin or glibenclamide, and it may be more attractive in general for this reason [33].”
BackgroundMethodMetformin treatment of type 2 diabetes mellitus in pregnancy: update on safety and efficacy
Polasek, T. M., Doogue, M. P., & Thynne, T. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618769831 · Cited by 21
Attenuation of maternal weight gain impacts infant birthweight: systematic review and meta-analysis
Bennett, C., Walker, R., Blumfield, M., Ma, J., Wang, F., Wan, Y., Gwini, S. M., & Truby, H. (2018) · Journal of Developmental Origins of Health and Disease · doi:10.1017/s2040174418000879 · Cited by 23
Sciannimanico, S. M., Grimaldi, F., Vescini, F., Pergola, G. D., Iacoviello, M., Licchelli, B., Guastamacchia, E., Giagulli, V. A., & Triggiani, V. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190507125847 · Cited by 22
Gestational Diabetes Mellitus - A Perspective
Seshiah, V., Balaji, V., & Balaji, M. S. (2011) · InTech eBooks · doi:10.5772/20770 · Cited by 22
Tieu, J., Coat, S., Hague, W. M., & Middleton, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007724.pub2 · Cited by 21
Self-citationPharmacotherapy for gestational diabetes
Patti, A. M., Giglio, R. V., Pafili, K., Rizzo, M., & Papanas, N. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1509955 · Cited by 19
“In the MiG (metformin use in GDM) trial [69], the primary composite outcome was neonatal morbidity.”
BackgroundDiabetes mellitus: The pathophysiology as a canvas for management elucidation and strategies
Iheagwam, F. N., & Iheagwam, O. T. (2025) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2025.100351 · Cited by 32
Use of hypoglycemic drugs during lactation.
(2009) · Europe PMC (PubMed Central) · Cited by 19
McGrath, R. T., Glastras, S. J., HOCKING, S. L., & Fulcher, G. R. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.051 · Cited by 21
Is it worth treating gestational diabetes: if so, when and how?
Vääräsmäki, M. (2016) · Diabetologia · doi:10.1007/s00125-016-3976-6 · Cited by 22
The impact of preinjury antithrombotic medication on hemostatic interventions in trauma patients
Kudo, D., Kushimoto, S., Shiraishi, A., Ogura, H., Hagiwara, A., & Saitoh, D. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.10.002 · Cited by 20
do Nascimento, I. B., Dienstmann, G., de Souza, M. L. R., Fleig, R., Hoffmann, C. B. P. C., & Silva, J. C. (2018) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0038-1675214 · Cited by 21
Dolatkhah, N., Hajifaraji, M., & Shakouri, S. K. (2018) · PubMed Central · Cited by 44
Comparative effectiveness of metformin versus insulin for gestational diabetes in New Zealand
Landi, S. N., Radke, S., Boggess, K., Engel, S. M., Stürmer, T., Howe, A. S., & Funk, M. J. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4907 · Cited by 21
“Our findings are consistent with prior studies, including the MiG trial (Appendix S10).(8) The most recent meta‐analysis of trials comparing metformin to insulin also calculated a summary estimate showing reduced risk of neonatal hypoglycemia associated with metformin.”
Resultdo Nascimento, I. B., Sales, W. B., Dienstmann, G., de Souza, M. L. R., Fleig, R., & Silva, J. C. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000251 · Cited by 20
“2% intolerance rate to the drug, with the metformin plus insulin use (16).”
BackgroundMusa, O. A. H., Syed, A., Mohamed, A. M., Chivese, T., Clark, J. M., Furuya‐Kanamori, L., Xu, C., Toft, E. S., Bashir, M., Abou‐Samra, A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105546 · Cited by 27
Diabetes in low-resourced countries
Ashwal, E., Hadar, E., & Hod, M. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2014.05.009 · Cited by 20
McGrath, R. T., Glastras, S. J., SCOTT, E. S., HOCKING, S. L., & Fulcher, G. R. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7030050 · Cited by 19
“This is a similar finding to other studies, wherein a significant proportion of women will not achieve glycaemic targets with metformin monotherapy alone [10,18].”
BackgroundResultInfluentialInsulin Resistance in Pregnancy: Implications for Mother and Offspring
Hernandez, T. L., Friedman, J. E., & Barbour, L. A. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-25057-7_5 · Cited by 25
Current management of gestational diabetes mellitus
Menato, G., Bo, S., Signorile, A., Gallo, M., Cotrino, I., Poala, C. B., & Massobrio, M. (2008) · Expert Review of Obstetrics & Gynecology · doi:10.1586/17474108.3.1.73 · Cited by 24
Chen, C., Huang, Y., Dong, G., Zeng, Y., & Zhou, Z. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1703943 · Cited by 18
Dasgupta, S., Banerjee, U., Mukhopadhyay, P., Maity, P., Saha, S., & Das, B. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102435 · Cited by 18
Stephansson, O., & Sandström, A. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13823 · Cited by 21
Is Glyburide Safe in Pregnancy?
Kimber-Trojnar, Ż., Marciniak, B., Patro-Małysza, J., Skórzyńska-Dziduszko, K., Poniedziałek‐Czajkowska, E., Mierzyński, R., Gałczyński, K., Trojnar, M. P., Leszczyńska‐Gorzelak, B., & Oleszczuk, J. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140330200254 · Cited by 20
Indonesian Clinical Practice Guidelines for Diabetes in Pregnancy
Purnamasari, D., Waspadji, S., Adam, J. M. F., Rudijanto, A., & Tahapary, D. L. (2013) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.028.01.02 · Cited by 27
Scifres, C., Mead‐Harvey, C., Nadeau, H. C. G., Reid, S., Pierce, S., Feghali, M. N., Myers, D. A., Fields, D. A., & Stoner, J. A. (2019) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2019.100050 · Cited by 19
Shuster, D. L., Shireman, L. M., Ma, X., Shen, D. D., Flood-Nichols, S. K., Ahmed, M. S., Clark, S. M., Caritis, S. N., Venkataramanan, R., Haas, D. M., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1749 · Cited by 20
Katsiki, N., Ferrannini, E., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154218 · Cited by 20
Lackovic, M., Milicic, B., Mihajlovic, S., Filimonovic, D., Jurisic, A., Filipovic, I., Rovcanin, M., Prodanovic, M., & Nikolic, D. (2021) · Medicina · doi:10.3390/medicina57080741 · Cited by 18
Metformin Safety in the Management of Gestational Diabetes
Marques, P., Carvalho, M. R., Luísa, & Guerra, S. (2014) · Endocrine Practice · doi:10.4158/ep14018.or · Cited by 22
Metformin for preventing gestational diabetes in women with polycystic ovarian syndrome.
Ainuddin, J. A., Kazi, S., Aftab, S., & Kamran, A. (2015) · PubMed · Cited by 19
Utz, B., Kolsteren, P. W., & Brouwere, V. D. (2016) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2016.01.020 · Cited by 18
“Oral metformin, which participants in the present study reported prescribing alone or in combination with insulin, is a safe alternative to insulin [21] andwas recently listed as a first-line treatment in the FIGO consensus guidelines [7].”
New modalities in the treatment of pregnancies complicated by diabetes: Drugs and devices
Chitayat, L., Jovanovič, L., & Hod, M. (2008) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2008.09.001 · Cited by 18
Vanlalhruaii, Dasgupta, R., Ramachandran, R., Mathews, J. E., Regi, A., Thomas, N., Gupta, V., Visalakshi, P., Asha, H. S., Paul, T. V., et al. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.01.002 · Cited by 17
Gestational diabetes mellitus and COVID-19: The epidemic during the pandemic
Mendez, Y. H., Radilla, L. A., Chabolla, L. D., Cruz, A. C., Luna, J., & Surani, S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i8.1178 · Cited by 18
Lin, S., Chang, S., Kuo, C., Lin, W., Chiou, M., & Huang, Y. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-03207-0 · Cited by 18
Management of Women with Polycystic Ovary Syndrome During Pregnancy
Valent, A. M., & Barbour, L. A. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.10.005 · Cited by 17
Feng, S., Wu, P., Song, W., Ding, H., Dunn, T. J., Gao, J., Labastida, J. A., Schlagal, C. R., & Ning, G. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.310695 · Cited by 19
Diabetes Mellitus Complicating Pregnancy
Landon, M. B., Catalano, P. M., & Gabbe, S. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1935-2.00039-9 · Cited by 23
Dunne, F., Newman, C., Devane, D., Smyth, A., Alvarez‐Iglesias, A., Gillespie, P., Browne, M., & O'Donnell, M. J. (2022) · Trials · doi:10.1186/s13063-022-06694-y · Cited by 18
“• Forty percent of participants in the placebo group will require insulin, based on the MiG trial [19] and local unpublished data from University Hospital Galway • Ability to detect a minimum of 30% relative risk reduction (RRR) in the proportion of women requiring insulin in the experimental (metformin) group (40 to…”
BackgroundMethodTheodoraki, A., & Baldeweg, S. E. (2008) · British Journal of Hospital Medicine · doi:10.12968/hmed.2008.69.10.31315 · Cited by 19
Placental dysfunction and stillbirth in gestational diabetes mellitus
Campbell, I. W., Duncan, C., Urquhart, R., & Evans, M. J. (2009) · The British Journal of Diabetes · doi:10.1177/1474651408101348 · Cited by 17
Metformin in gestational diabetes: physiological actions and clinical applications
Mason, T., Alesi, S., Fernando, M., Vanky, E., Teede, H. J., & Mousa, A. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01049-w · Cited by 20
“In the early landmark Metformin in Gestational diabetes (MiG) trial, comprising 751 pregnant women with GDM, Rowan et al. 117 reported reduced gestational weight gain and a patient prefer ence for metformin over insulin, although no difference in the primary outcome was observed (which was a composite of neonatal hyp…”
InfluentialArias-Sánchez, C., Pérez-Olmos, A., Reverte, V., Hernández, I., Cuevas, S., & Llinás, M. T. (2025) · Antioxidants · doi:10.3390/antiox14080928 · Cited by 22
“Randomized controlled trials, such as the MiG (metformin in gestational diabetes) study, have demonstrated its maternal-fetal safety and efficacy comparable to insulin [142].”
Zhang, Y., Liu, X., Yang, L., & Zou, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.596145 · Cited by 16
“3% of the women received supplemental insulin, and the perinatal complications did not differ between the two groups (Rowan et al., 2008).”
BackgroundGayatri, V., Prasad, M. K., Mohandas, S., Nagarajan, S., Kumaran, K., & Ramkumar, K. M. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176241 · Cited by 19
Alhusayen, R. O., Dienes, S., Lam, M., Alavi, A., Alikhan, A., Aleshin, M. A., Bahashwan, E., Daveluy, S. D., Goldfarb, N. I., Garg, A., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.11.071 · Cited by 19
Corbould, A. M., Swinton, F., Radford, A., Campbell, J., McBeath, S., & Dennis, A. E. (2012) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12018 · Cited by 16
Pregnancy outcomes after metformin treatment for gestational diabetes: a case-control study
Balani, J., Hyer, S. L., Johnson, A., & Shehata, H. A. (2012) · Obstetric Medicine · doi:10.1258/om.2012.110092 · Cited by 16
Correia‐Branco, A., Keating, E., & Martel, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.038 · Cited by 17
PREGNANCY IN DIABETES AND KIDNEY DISEASE
Bramham, K., & Rajasingham, D. (2012) · Journal of Renal Care · doi:10.1111/j.1755-6686.2012.00270.x · Cited by 20
“Both metformin and glibenclamide cross the placenta and may cause neonatal hypoglycaemia, but is uncommon with metformin (Rowan et al. 2008).”
BackgroundFeitosa, A. C. R., Sampaio, L. N., Batista, A. G. L., & Pinheiro, C. B. (2013) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1590/s0100-72032013000300004 · Cited by 18
Talaulikar, V. S., Tang, T. H., & Yasmin, E. (2016) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000312 · Cited by 22
Bowker, S. L., Savu, A., Yeung, R. O., Johnson, J. A., Ryan, E. A., & Kaul, P. (2017) · Diabetic Medicine · doi:10.1111/dme.13394 · Cited by 17
Gray, S. G., Sweeting, A., McGuire, T., Cohen, N. D., Ross, G. P., & Little, P. J. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12660 · Cited by 17
“alternative for GDM in some clinical environments, as shown in the studies by Rowan et al.(39) Countries in Europe (e.”
BackgroundMethodMousa, A., Løvvik, T. S., Nikkinen, H., Carlsen, S. M., Morin-Papunen, L. C., Tertti, K., Rönnemaa, T., Syngelaki, A., Nicolaides, K. H., Shehata, H. A., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-036981 · Cited by 17
Self-citationLassi, Z. S., & Bhutta, Z. A. (2013) · Expert Review of Obstetrics & Gynecology · doi:10.1586/17474108.2013.841453 · Cited by 16
Successful pregnancy outcomes in a patient with type A insulin resistance syndrome
Enkhtuvshin, B., Nagashima, S., Saito, N., Wakabayashi, T., Ando, A., Takahashi, M., Sakai, K., Yamamuro, D., Nagasaka, S., Tamemoto, H., et al. (2014) · Diabetic Medicine · doi:10.1111/dme.12659 · Cited by 17
Oral hypoglycemic therapy: Understanding the mechanisms of transplacental transfer
Pollex, E. K., Feig, D. S., & Koren, G. (2010) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767050903550881 · Cited by 16
Metformin treatment for gestational diabetes
Hyer, S. L., Balani, J., Johnson, A., & Shehata, H. A. (2009) · The British Journal of Diabetes · doi:10.1177/1474651409346767 · Cited by 18
Novel therapies for diabetes mellitus in pregnancy
Feghali, M. N., & Scifres, C. (2018) · BMJ · doi:10.1136/bmj.k2034 · Cited by 17
II Consenso de la Sociedad Chilena de Endocrinología y Diabetes sobre resistencia a la insulina
Felipe Pollak, C., Araya, V., Lanas, A., SAPUNAR, J., Arrese, M. A., Aylwin, C. G., Bezanilla, C. G., Carrasco, E., Fernando Carrasco, N., Ethel Codner, D., et al. (2015) · Revista médica de Chile · doi:10.4067/s0034-98872015000500012 · Cited by 34
Harris, K., Desai, N., Gupta, M., Xue, X., Chatterjee, P. K., Rochelson, B. L., & Metz, C. N. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0115-9 · Cited by 16
“Although it has been safely used for treating GDM in other countries since the 1970s [48], metformin has only been regularly prescribed to women with GDM in the US within recent years [49].”
MethodSingh, N., Madhu, M., Vanamail, P., Malik, N., & Kumar, S. (2017) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1358_15 · Cited by 24
Longer-term outcomes in offspring of GDM mothers treated with metformin versus insulin
Zhen, X. M., Li, X., & Chen, C. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.07.002 · Cited by 17
Helal, K. F., Badr, M. S., Rafeek, M. E.-S., Elnagar, W. M., & Lashin, M. E.-B. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05430-3 · Cited by 17
Hashim, H. A., Wafa, A. M., & Rakhawy, M. E. (2010) · Gynecological Endocrinology · doi:10.3109/09513590.2010.488771 · Cited by 15
RetractedOral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes
Brown, J., Martis, R., Hughes, B., Rowan, J., & Crowther, C. A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011967 · Cited by 15
Self-citationNon-pharmacological management of gestational diabetes: The role of myo-inositol
Guardo, F. D., Currò, J. M., Valenti, G., Rossetti, P., Di Gregorio, L. M., Conway, F., Chiofalo, B., Garzon, S., Bruni, S., & Rizzo, G. (2020) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2019-0111 · Cited by 14
Gilbert, L., Nikolaou, A., Quansah, D. Y., Rossel, J., Horsch, A., & Puder, J. J. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.105095 · Cited by 17
“Indeed, previous research has shown that metformin is better accepted in women with GDM and that insulin is more burdensome (Rowan et al., 2008).”
BackgroundResultInfluentialFu, J. M., Tabbara, N., TOMLINSON, G. A., Murphy, K. E., Hamilton, J. K., & Feig, D. S. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088653 · Cited by 15
Metformin for the management of gestational diabetes mellitus
Singh, K. P., Rahimpanah, F., & Barclay, M. (2015) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12311 · Cited by 14
Marcadores para o diagnóstico e tratamento de 924 gestações com diabetes melito gestacional
Detsch, J. M., Almeida, A. C. R., Bortolini, L. G. C., Nascimento, D. J., Oliveira, F. C., & Rea, R. R. (2011) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302011000600005 · Cited by 31
Pharmacological Management of Gestational Diabetes Mellitus
Bergel, R., Hadar, E., Toledano, Y., & Hod, M. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0802-y · Cited by 18
Prevention of Excessive Gestational Weight Gain and Postpartum Weight Retention
Nicodemus, N. A. (2018) · Current Obesity Reports · doi:10.1007/s13679-018-0312-0 · Cited by 16
Research progress of metformin in gestational diabetes mellitus: a narrative review
Ouyang, H., Al-Mureish, A., & Wu, N. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-192 · Cited by 19
“A large randomized controlled trial (RCT) published in 2008 showed that metformin alone or insulin used in combination with metformin are safe and effective treatment options for women with GDM (14).”
BackgroundDeussen, A. R., Louise, J., & Dodd, J. M. (2022) · Pediatric Obesity · doi:10.1111/ijpo.12974 · Cited by 16
“The MIG randomized trial-compared metformin with insulin for the treatment of women with gestational diabetes.(25) Assessments at two years of age identified children exposed to metformin to had larger subscapular skinfold thickness and mid-upper arm circumference measures.”
MethodManagement of diabetes and pregnancy – When to start and what pharmacological agent to choose?
Hiersch, L., & Yogev, Y. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2014.04.020 · Cited by 16
Improving pregnancy outcome in obese women
Denison, F. C., & Chiswick, C. A. (2011) · Proceedings of The Nutrition Society · doi:10.1017/s0029665111001637 · Cited by 16
Metformin effects on treatment satisfaction and quality of life in gestational diabetes
Latif, L., Hyer, S. L., & Shehata, H. A. (2013) · The British Journal of Diabetes · doi:10.1177/1474651413493933 · Cited by 15
Anti-diabetic drug utilization of pregnant diabetic women in us managed care
Knox, C. A., Delaney, J. A., & Winterstein, A. G. (2014) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-14-28 · Cited by 16
“Furthermore, the majority of the metformin safety studies have been completed in women with polycystic ovarian syndrome or gestational diabetes, not in women with pre-existing diabetes, and have not evaluated pregnancy outcomes (pre-term labor, preeclampsia, cesarean section delivery) as safety endpoints [24,26].”
BackgroundScavini, M., & Secchi, A. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01364-z · Cited by 16
“Metformin for the treatment of GDM has been tested in RCTs with reassuring long-term follow-up of the offspring [17, 18].”
Caissutti, C., Saccone, G., Khalifeh, A., Mackeen, A. D., Lott, M., & Berghella, V. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1449203 · Cited by 13
Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Rowan, J. (2015) · Annals of Human Biology · doi:10.3109/03014460.2014.959999 · Cited by 13
“At birth, for the women in the metformin group, compared with the insulin treatment, there were no increases in perinatal complications or differences in infant anthropometry (Rowan et al., 2008).”
BackgroundResultSelf-citationMassalha, M., Iskander, R., Hassan, H., Spiegel, E., Erez, O., & Nachum, Z. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1527076 · Cited by 15
“A follow-up study (178) found similar developmental outcomes by 2 years of age (191).”
Metadata
- Authors
- Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P.
- Affiliations
- Auckland City Hospital (NZ)
- Women's and Children's Hospital (AU)
- Auckland University of Technology (NZ)
- University of Auckland (NZ)
- Christchurch Hospital (NZ)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-08
- Volume
- 358
- Issue
- 19
- Pages
- 2003-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003621575
- Cited by
- 1,291
- References
- 33
- Citations by year
- 2026: 49 · 2025: 60 · 2024: 52 · 2023: 65 · 2022: 63 · 2021: 90 · 2020: 67 · 2019: 66 · 2018: 105 · 2017: 125 · 2016: 68 · 2015: 82 · 2014: 69 · 2013: 62 · 2012: 56
- FWCI
- 78.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, insulin, gestational diabetes mellitus, neonatal hypoglycemia, perinatal complications, maternal glycemic control, postpartum glucose tolerance, treatment acceptability, treatment preferences, neonatal respiratory distress, phototherapy
- MeSH terms
- Adult, Drug Therapy, Combination, Female, Gestational Age, Humans, Hypoglycemia, Hypoglycemic Agents, Infant, Newborn, Insulin, Jaundice, Neonatal, Metformin, Pregnancy, Pregnancy Complications, Cardiovascular, Pregnancy Outcome, Diabetes, Gestational, Patient Satisfaction, Premature Birth
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.